Sleep

The symptoms of serotonin syndrome often include autonomic dysfunction, neuromuscular excitation, and altered mental status.

Serotonin syndrome generally occurs within 6 hours of a change in dose or addition of medication.

The FDA approved daridorexant in January 2022 to treat insomnia after it showed improvements in changes in latency to persistent sleep and wake after sleep onset.

FT218 is an investigational formulation of sodium oxybate that is designed to be taken once at bedtime for the treatment of excessive daytime sleepiness for individuals with narcolepsy.

Phase 3 REST-ON Trial data show that the medication demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared with the placebo.

OTC sleep aids may help treat an occasional sleepless night.

Sleeplessness Is prevalent, and many Individuals struggle to find effective relief and treatment.

Suvorexant (Belsomra) is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Although pharmacotherapy is considered for the treatment of insomnia, medication should not be the sole treatment for individuals diagnosed with insomnia.

Those with the disorder during gestation and who were examined 2 to 7-years after delivery had a more than 3-fold increased risk for incident high blood pressure, results of the analysis show.

Prior studies indicate that CPAP treatment can significantly decrease sleepiness and depression while also protecting against high blood pressure.

Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents.

New study results may help improve automated methods for detecting these spindles and correlating them with brain function, investigators say.

Daridorexant (Quviviq) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Daridorexant (Quviviq, Idorsia Pharmaceuticals) is indicated for adults who experience difficulties with sleep onset and/or sleep maintenance.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Natural melatonin sends messages to the receptor agonist in the brain and other areas of the body to help control the sleep and wake cycles.

Results of a study by the American Heart Association show a genetic predisposition may lead to an association between sleeplessness and brain bleeding.

This is the first large-scale transdiagnostic study of objectively measured sleep and mental health.

Unisom is an antihistamine that reduces the effects of natural chemical histamine in the body.

The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Washington State University study results show that slumber-deprived individuals had more difficulty reducing the emotions they felt when so instructed than those who slept normally.

The medication has both short- and long-term effects on improving excessive sleepiness.

The paper reviews the safety profile of solriamfetol in treating ES associated with OSA or narcolepsy and discusses subject areas such as pharmacology, clinical efficacy, and tolerability of the drug.

Axsome Therapeutics continues to explore its narcolepsy drug after the FDA granted it orphan drug designation.